Prevention and treatment of hypogonadism-associated bone loss and bone metastases by OPG-Fc in a model of mixed osteolytic/osteoblastic metastases

被引：0
|
作者：
Padalecki, S. S. [1 ]
Grubbs, B. [1 ]
Goins, B. [1 ]
Soundarajan, A. [1 ]
Mundy, G. R. [2 ]
Dougall, W. [3 ]
机构：
[1] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX USA
[2] VUMC, Nashville, TN USA
[3] Amgen Inc, Cambridge, MA USA
来源：
JOURNAL OF BONE AND MINERAL RESEARCH | 2007年 / 22卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
S311
引用
收藏
页码：S115 / S115
页数：1
相关论文
共 50 条
  • [41] Clodronate prevents osteolytic breast cancer bone metastases in a mouse model:: Effects on bone mineral density.
    Käkönen, SM
    Isaksson, P
    Lakkakorpi, PT
    Österman, T
    Malmström, C
    Suominen, M
    Aho, E
    Sjöholm, B
    Hokkanen, S
    Hannuniemi, R
    JOURNAL OF BONE AND MINERAL RESEARCH, 2003, 18 : S113 - S113
  • [42] An algorithm model for management of bone metastases and associated pain
    Blum, RH
    Bhatia, A
    Fleishman, S
    Portenoy, R
    JOURNAL OF BONE AND MINERAL RESEARCH, 2005, 20 : P10 - P10
  • [43] Model of spontaneous osteolytic bone metastases with HTLV-1 Tax transgenic mice
    Gao, L
    Deng, H
    Zhao, H
    Angela, H
    Harding, J
    Ratner, L
    Weilbaecher, K
    AIDS RESEARCH AND HUMAN RETROVIRUSES, 2005, 21 (05) : 504 - 505
  • [44] ClodronateA Review of its Use in the Prevention of Bone Metastases and the Management of Skeletal Complications Associated with Bone Metastases in Patients with Breast Cancer
    Toni M. Dando
    Lynda R. Wiseman
    Drugs & Aging, 2004, 21 : 949 - 962
  • [45] Clodronate - A review of its use in the prevention of bone metastases and the management of skeletal complications associated with bone metastases in patients with breast cancer
    Dando, TM
    Wiseman, LR
    DRUGS & AGING, 2004, 21 (14) : 949 - 962
  • [46] Detection of bone metastases in breast cancer by 18FDG PET:: Differing metabolic activity in osteoblastic and osteolytic lesions
    Cook, GJ
    Houston, S
    Rubens, R
    Maisey, MN
    Fogelman, I
    JOURNAL OF CLINICAL ONCOLOGY, 1998, 16 (10) : 3375 - 3379
  • [47] Evaluating the effects of mixed osteolytic/osteoblastic metastasis on vertebral bone quality in a new rat model
    Wise-Milestone, Lisa
    Akens, Margarete K.
    Rosol, Thomas J.
    Hojjat, Seyed-Parsa
    Grynpas, Marc D.
    Whyne, Cari M.
    JOURNAL OF ORTHOPAEDIC RESEARCH, 2012, 30 (05) : 817 - 823
  • [48] Detection of bone metastases in breast cancer by 18-FDG PET: Differing metabolic activity in osteoblastic and osteolytic lesions
    Cook, G
    Houston, S
    Rubens, R
    Maisey, M
    Fogelman, I
    JOURNAL OF BONE AND MINERAL RESEARCH, 1997, 12 : P310 - P310
  • [49] Antitumor efficacy of the RANK ligand inhibitor OPG-Fc in the MDA-231 breast cancer and PC3 prostate cancer experimental osteolytic metastases models.
    Miller, R
    Jones, J
    Tometsko, M
    Armstrong, A
    Zhang, N
    Leal, J
    Trueblood, E
    Dougall, W
    JOURNAL OF BONE AND MINERAL RESEARCH, 2005, 20 (09) : S117 - S117
  • [50] The RANKL inhibitor OPG-Fc delays the de novo establishment of breast cancer skeletal metastases in an MDA-MB-231 mouse model
    Canon, Jude
    Bryant, Rebecca
    Miller, Robert
    Erwert, Ryan
    Roudier, Martine
    Coxon, Angela
    Dougall, William
    CANCER TREATMENT REVIEWS, 2008, 34 : S60 - S60
12345